Matthew Halbert

University of Pittsburgh — United States

Medicine · Health Sciences

7h-index444citations29works0.12yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Glioma Diagnosis and Treatment(18), Cancer, Hypoxia, and Metabolism(5), Epigenetics and DNA Methylation(3), Cancer Genomics and Diagnostics(3), Ferroptosis and cancer prognosis(3)

Publications29 total

TMET-39. DUAL TARGETING OF MAP KINASE SIGNALING AND METABOLISM IS A THERAPEUTIC VULNERABILITY IN PEDIATRIC DIFFUSE MIDLINE GLIOMAS
Neuro-Oncology·2024Open Access
TMET-22. OVERCOMING RESISTANCE: PANOBINOSTAT SENSITIZES 2DG-RESISTANT PEDIATRIC HIGH-GRADE GLIOMAS WITH H3.3 K27M/G34R MUTATIONS TO APOPTOSIS
Neuro-Oncology·2024Open Access
DIPG-85. MALT1 IN H3K27-ALTERED DIFFUSE MIDLINE GLIOMA
Neuro-Oncology·2024Open Access
DIPG-79. METTL16 AS A THERAPEUTIC VULNERABILITY IN H3K27M MUTANT DMG CELLS
Neuro-Oncology·2024· 1 citedOpen Access
Abstract PO2-06-10: Prevalence of genomic alterations in Xerna tumor microenvironment subtypes in triple negative breast cancer patients
Cancer Research·2024
Abstract 2037: Enhanced chemosensitivity to DNA-damaging agents in human high-grade glioma through 2-DG treatment
Cancer Research·2024
Abstract A002: MALT1 as a regulator of tumor progression in H3K27-altered diffuse midline glioma
Cancer Research·2024
An ERK5-PFKFB3 axis regulates glycolysis and represents a therapeutic vulnerability in pediatric diffuse midline glioma
Cell Reports·2023· 15 citedOpen Access
219 Prevalence of genomic alterations in Xerna<sup>TM</sup> tumor microenvironment subtypes in colorectal cancer patients
Regular and Young Investigator Award Abstracts·2023Open Access
An Overview of Nanotherapeutic Drug Delivery Options for the Management of Glioblastoma
Journal of Nanotheranostics·2023· 5 citedOpen Access
DIPG-36. H3K27M HISTONE MUTANT GLIOMAS ARE SENSITIVE TO METHIONINE LOSS AND MAT2A INHIBITION THROUGH A NOVEL FEEDBACK MECHANISM BETWEEN AMD1 AND METTL16
Neuro-Oncology·2023Open Access
DIPG-46. TARGETING THE METABOLIC ERK5-PFKFB3 AXIS IN PEDIATRIC DIFFUSE MIDLINE GLIOMA
Neuro-Oncology·2023· 1 citedOpen Access
DIPG-08. THE LANDSCAPE OF TUMOR CELL STATES AND SPATIAL ORGANIZATION IN H3-K27M MUTANT DIFFUSE MIDLINE GLIOMA ACROSS AGE AND LOCATION
Neuro-Oncology·2023· 1 citedOpen Access
Targeting mitochondrial energetics reverses panobinostat‐ and marizomib‐induced resistance in pediatric and adult high‐grade gliomas
Molecular Oncology·2023· 9 citedOpen Access
Author response for "Targeting mitochondrial energetics reverses panobinostat‐ and marizomib‐induced resistance in pediatric and adult high‐grade gliomas"
2023
Sorting nexin 10 sustains PDGF receptor signaling in glioblastoma stem cells via endosomal protein sorting
JCI Insight·2023· 18 citedOpen Access
The landscape of tumor cell states and spatial organization in H3-K27M mutant diffuse midline glioma across age and location
Nature Genetics·2022· 174 citedOpen Access
DDDR-10. INHIBITING INSULIN SIGNALING REVERSES RESISTANCE TO PI3K-MTOR INHIBITORS IN AGGRESSIVE PEDIATRIC HIGH-GRADE GLIOMAS
Neuro-Oncology·2022Open Access
159 Xerna tumor microenvironment subtypes as a biomarker in lung cancer patients
Regular and Young Investigator Award Abstracts·2022Open Access
TMET-09. LOSS OF MAT2A COMPROMISES METHIONINE METABOLISM AND REPRESENTS A VULNERABILITY IN H3K27M MUTANT GLIOMAS
Neuro-Oncology·2022Open Access
page 1 of 2Next →

Frequent Co-authors

Sameer Agnihotri(22), Taylor Gatesman(17), Ian F. Pollack(13), Esther P. Jane(10), Daniel R. Premkumar(10), Andrea Cruz(10), Stephen C. Mack(10), Stephanie M. Casillo(9), Brian Golbourn(8), Steven J. Mullett(8), Ann-Catherine J. Stanton(7), Stacy G. Wendell(7), Srinidhi Varadharajan(6), Jeremy N. Rich(5), Katharine Halligan(5), Robert F. Koncar(5), Yue‐Fang Chang(5), Frank S. Lieberman(5), James Felker(5), Kelsey C. Bertrand(5)